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Congenital vascular anomalies of the liver 
refer to abnormal connections between the 
three vascular entities, i.e. the incoming 
portal vein, hepatic artery, and the outgoing 
hepatic veins (i.e. the systemic circulation) 
and their respective branches. The clinical 
implications of such anomalies can be 
diverse or silent and depend on alteration 
of blood flow and direction. In addition, 
we will consider actual parenchymal 
lesions composed mainly of blood vessels – 
haemangiomas – as many have their origins 
in prenatal life.
As there are 3 vascular systems within 
the liver there are 3 possible anomalous 
connections:
• portosystemic shunts
• arteriovenous shunts
• arterioportal shunts.
Congenital 
portosystemic shunt
Congenital portosystemic shunts (CPSs) 
are vascular malformations resulting in 
the diversion of portal venous blood from 
the liver sinusoids and into the systemic 
circulation. The first reported case was by 
John Abernethy, a surgeon at St 
Bartholomew’s Hospital, London, who 
described an abnormal venous connection 
between the portal vein as it entered the 
liver and the inferior vena cava (IVC)  in its 
intrahepatic course.[1] Howard and Davenport 
presented one of the first case series in the 
literature in 1997 and suggested that such 
portosystemic shunts be given the eponym 
of ‘Abernethy malformation’ in recognition.[2] 
Experience with other types of portosystemic 
shunts highlighted the variation in anatomy 
in these patients.  The most frequent CPS is 
an ‘H’ type venous connection from the back 
of the bifurcation of the portal vein directly 
into the IVC as it enters the liver. This may be 
associated with an intrahepatic portal venous 
system of varying size. The caudate lobe 
is often smaller than usual and is usually 
traversed by the shunt. 
Originally CPSs were felt to be very rare, 
with only 15 clinical cases reported up to 
the 1990s;[2] however, widespread use of 
abdominal ultrasound (US) scanning has 
shown them to be much more common 
than was initially thought, with 316 cases 
identified in the most recent systematic 
review of the literature.[3] Data on the actual 
incidence of CPSs are limited. The only 
estimate has been extrapolated from studies 
of hypergalactosaemia screening. One study 
of 145 000 infants in which 5 cases of 
CPSs were found with hypergalactosaemia, 
thus yielding an approximate incidence 
of 1 in 30 000 live births.[4] However, 
two factors may indicate that this figure 
is unreliable. Firstly, the cases identified 
in this study resolved spontaneously and 
were likely portohepatic shunts; thus this 
calculation may overestimate the clinically 
significant CPSs. Secondly, the majority of 
patients with CPSs do not present with 
hypergalactosaemia and may have normal 
blood galactose. The study may have missed 
a significant number of patients with CPSs in 
their cohort. Further epidemiological studies 
are required for an accurate estimate of the 
incidence of CPSs. 
Together with the overall increase in 
reported cases, multiple classification 
systems have also emerged. Differences 
between classification methods are based 
on small variations in anatomy or alternate 
prespectives of the same shunts (e.g. 
classifying based on the origin of the shunt 
in the portal system v. based on the insertion 
of the shunt in the systemic circulation). The 
two most widely used classification systems 
are summarised in Table 1. The Chicago 
Classification’s latest iteration[5] divides CPSs 
broadly into type I – end-to-side implying 
little or no intrahepatic portal venous system, 
and type II – side-to-side with preservation 
of a variable amount of intrahepatic flow 
(Fig. 1). Our current understanding suggests 
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Fig. 1. Radiological portocavograms with balloon occlusion of the shunt showing (A) no evidence of an 
intrahepatic portal venous system (Type I) and  (B) re-opening of an apparently normal portal venous 
system (Type II ).
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more of a continuum – severe hypoplasia of the intrahepatic portal 
tree may render it invisible on imaging but complete absence is highly 
unlikely. The other noteworthy classification is that of Blanc et al.[6] 
from Bicêtre, Paris, who proposed a complex surgical classification 
focusing on the subtle differences of the insertion of the shunt onto 
the IVC or hepatic veins. However, the Blanc classification was 
formed using both radiology and intraoperative findings for each 
individual patient, thus limiting its accuracy preoperatively when 
only radiological investigations are available.  
Persistence of the ductus venosus is a CPS in which the normal 
prenatal connection between the left portal vein and hepatic veins 
fails to close spontaneously and involute. This ‘shunt’ circumvents 
the liver sinusoids, thereby directing oxygenated blood from the 
placental circulation via the left hepatic vein to the right heart.
Clinical features
An incidental ultrasound abnormality is probably the most common 
form of presentation these days – often as part of an investigation into 
persistent jaundice. Otherwise, CPS becomes apparent in infants with 
other congenital, particularly cardiac, abnormalities. Table 2 outlines 
the most frequent associations and complications of CPS.
Most symptoms of CPS can be attributed to either the effects of 
shunted mesenteric blood directly into the circulation – measurement 
of serum ammonia is the best surrogate of this – or from the 
development of tumours within the liver, probably as a result of an 
increased arterial contribution to the sinusoidal circulation. 
Loss of the hepatic ‘filter’ causes neuro-psychological symptoms 
ranging from frank encephalopathy through drowsiness, poor attention 
span and, in infants and children, developmental delay in up to 25% of 
cases. Up to 15% of cases develop hypoxia, platypnoea (breathlessness 
which worsens on sitting up) or dyspnoea due to hepatopulmonary 
syndrome or pulmonary hypertension. The actual mechanism at the 
molecular level in either symptom complex is not known.  While 
hyperammonaemia is certainly reflective of the shunt, it is probably not 
the specific agent of pathology. 
The other main presentation of CPSs is with a liver tumour 
(Fig. 2).[2,5,7] Such patients develop abdominal pain and/or a palpable 
mass prompting investigation, with the finding of a tumour and a 
co-incident CPS. The most common tumours are benign, such as focal 
nodular hyperplasia and adenomas,[7,8] but malignancy is also possible 
– typically hepatoblastomas[5] and hepatocellular carcinomas.[3]  
Investigations and management
Laboratory investigations should include a full blood count, serum 
biochemistry, albumin, coagulation screen, and of course ammonia 
levels (Fig. 3). 
Table 1. Classifications of congenital portosystemic shunts
Lautz et al. 2010[8] – The Chicago Classification
Type I – end-to-side with apparent absence of the portal vein
 Ia – SMV and splenic vein do not join prior to implanting into 
systemic circulation
 Ib – SMV and splenic vein join prior to implanting into the 
systemic circulation
Type II – partial shunt with preserved portal flow 
IIa – arising from the left or right portal vein
 IIb – arising from the main portal vein, its bifurcation or the 
splenomesenteric confluence
IIc – arising from the mesenteric, gastric, or splenic vein
Blanc et al. 2013[6] –The Paris Classification
Extrahepatic 
• End-to-side shunt – with no apparent portal venous flow 
(similar to Lautz et al.[8]  Type I)
• Side-to-side shunt – similar in appearance but with preserved 
portal flow
• H-type – shunt going through the caudate lobe with preserved 
portal flow
Intrahepatic
• Portohepatic – any communication from a portal venous branch 
to a hepatic venous branch
• Persistent ductus venosus 
SMV = superior mesenteric vein.
Table 2. Associations and complications in infants and 
children with infantile hepatic haemangiomas (Adapted from 
Kulungowski et al.[16])
Focal, % Multifocal, % Diffuse, %
Cutaneous lesions 15 77 53
Prenatal detection 30 0 0
Hypothyroidism 0 21 100
Heart failure 27 18 56
Shunt 38 16 39
Fig. 2. Axial view of liver magnetic resonance imaging scan showing the 
shunt (white arrow) and associated hepatic tumours (black arrows). 
Initial evaluation:
• Full blood count
• Liver function tests
• Coagulation tests
• Serum ammonia level
• Bile acid level
Consider observation if:
• Age <2 years
• Small shunt from branch of PV
• Normal serum ammonia
• No  liver masses
Endovascular
Options include:
• Amplatzer plug
• Coil embolisation
• Covered stent graft in IVC
Type I shunt:
• Manage symptoms
• Consider transplant
Balloon occlusion
Question:
Intrahepatic portal venous 
system?
Operation:
Explore test occlusion assess 
for PHT
   No - complete ligation
   Yes - banding and staged 
              
Further evaluation:
Neurocognitive dysfunction
• Psychometric testing
• Brain MRI
Liver mass
• Alpha-fetoprotein
• Biopsy
Cardiopulmonary symptoms
• Echocardiography
• Right-heart catheterisation
Imaging:
Doppler US
CT or MRA
Surgery
closure
Fig. 3. Clinical algorithm for the investigation and management of a suspected 
congenital portosystemic shunt. (US = ultrasonography; CT = computed 
tomography, MRA = magnetic resonance arteriography; MRI = magnetic 
resonance imaging; IVC = inferior vena cava; PHT = portal hypertension.)
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Cross-sectional imaging (computed 
tomography (CT) scan or magnetic 
resonance imaging (MRI)) is required to 
define the anatomy and caval or portal 
venography and is essential prior to any form 
of direct intervention. The latter defines the 
size of the connection and in the event 
of temporary occlusion it shows whether 
the latent intrahepatic portal venous system 
can handle the restored mesenteric blood 
flow without clinically significant portal 
hypertension.  
Intrahepatic CPS and patent ductus 
venosus do have the potential for 
spontaneous closure within the first 2 
years of life.[3] CPSs with shunts persisting 
beyond 2 years of age should be treated, 
even if apparently asymptomatic. Options 
for closure are dependent on available 
expertise and the anatomy of the shunt but 
radiological endovascular closure is typically 
used for those CPSs with a long intrahepatic 
course (Fig. 4). CPSs such as the Abernethy 
shunt, with a short and wide connection, 
usually require open surgical ligation, either 
in one stage or following partial closure by 
banding if on-table measured mesenteric 
pressures are too high to be sustainable, 
e.g. >20 mmHg, with normal portal venous 
pressure being <5 mmHg. 
Those who have already developed 
tumours will require resections but should 
still be closely monitored for the development 
of other tumours after surgery. Shunt closure 
in itself has also been reported to have led to 
regression of benign tumours.[10] 
For those CPSs considered to be 
uncorrectable by conventional surgical 
or radiological means, or through the 
development of unresectable or multiple 
malignancy, liver transplant may still have 
a role. This had been used for up to 25% of 
CPSs in one recent systematic review.[3] 
Arterioportal fistulas
Congenital arterioportal fistulas (APFs) are 
rare[11] and usually present with features and 
complications of portal hypertension due 
to increased ‘arterialisation’ of the portal 
venous system. Rarely, if flow is sufficient 
and a ductus venosus remains patent, high-
output cardiac failure may result. Congenital 
APFs are less common than the acquired 
version, which usually follows penetrating 
liver trauma or iatrogenically with a core liver 
biopsy needle. Protein-losing enteropathy 
and malabsorption have also been observed 
but are not common findings. Ultrasound 
and Doppler flow studies are key in the 
assessment of patients in whom pulsatile 
and often reversed portal flow is observed. 
Cross-sectional imaging supplements 
the anatomical definition and hepatic 
angiography can be followed by endovascular 
treatment. Congenital APFs have not been 
reported to close spontaneously and should 
be treated to limit the effects of portal 
vein arterialisation, which can become 
irreversible. Treatment is aimed at closure 
of the shunt via an endovascular or an open 
surgical approach involving ligation of the 
hepatic artery. Rarely, a patient with complex 
multiple bilobar APFs can be challenging 
to treat by embolisation and thus a partial 
hepatectomy or even liver transplantation 
may be considered. The outcome is largely 
favourable but perhaps 10% of patients 
can be shown to have persistent portal 
hypertension but now owing to portal vein 
thrombosis secondary to abrupt withdrawal 
of the arterial input.
Arteriovenous 
malformation (AVMs)
True isolated arteriovenous malformations 
(AVMs) are exceedingly rare and the 
literature is limited to few case reports.[8] 
Often, the literature has mistakenly 
categorised infantile hepatic haemangiomas 
(IHH) as AVMs, as they often have an 
element of arteriovenous shunting. However 
,the former are tumours of markedly 
different aetiology and have a distinct clinical 
evolution.  True AVMs have been associated 
with hereditary haemorrhagic telangiectasia 
(Osler-Weber Rendu syndrome) and children 
with trisomy 21.[12] They are present at birth, 
at which point they are often clinically silent, 
and grow proportionally with the child. The 
most frequent complication is high-output 
cardiac failure and anaemia, but bleeding, 
embolism, and pain may occur. On imaging, 
they are seen as dysplastic arteries and veins 
with high flow and, importantly, do not have 
an associated soft-tissue mass. Treatment 
is aimed at closing the shunting vessels 
and is most commonly attempted by an 
endovascular approach, but surgical options 
may still be required. Due to the limited 
number of reported cases in the literature, it 
Fig. 4. Endovascular closure of congenital portosystemic shunts. Patient 1: (A) Venogram demonstrated 
a large fistula between the portal vein and right atrium. (B) Intrahepatic branches of the portal vein 
were visualised following balloon occlusion of the shunt. (C) Postoperative computed tomography 
scan showing an Amplatzer plug which successfully occluded the shunt. Patient 2: (D) Coil embolisation 
is an alternative endovascular modality for shunt closure. (Reproduced here with permission from 
Lautz TB, Superina RA. Congenital anomalies of liver vasculature. In: Davenport M, 
Superina RA, Heaton ND, eds. Surgery of the Liver, Bile Ducts and Pancreas in Children. 3rd ed. 
Boca Raton: CRC Press, 2017:267-278.
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is not possible to accurately state the prognosis; however, one group 
found that 2 of 4 of their patients died (1 immediately after birth and 
1 intraoperatively) and that all of them had presented with symptoms 
of cardiac failure.[13]
Infantile hepatic haemangiomas 
Infantile hepatic haemangiomas (IHHs) are benign endothelial 
tumours, predominantly affecting the skin. IHHs affect up to 5% of 
white infants. While they are most commonly found in the cutaneous 
form, visceral involvement is not infrequent; the latter affects mainly 
the liver, with some reports of tumours in the brain, lungs and eyes. 
IHHs were initially described as ‘haemangioendotheliomas’ by 
Kunstadter[14] in a series of 15 cases in 1933 and are now recognised as 
the most common benign vascular tumour of infancy.[16] Despite this, 
IHHs have remained somewhat of an enigma because of significant 
variation in clinical course and a wide variation in nomenclature 
over time. These lesions are, however, distinct from both epitheloid 
haemangioendotheliomas, which is a multifocal, proliferative low-
grade malignant tumour with metastatic potential, and adult liver 
haemangiomas, which are vascular malformations – neither of these 
lesions involute. As such, the term ‘infantile hepatic haemangioma’ 
has been adopted owing to the clinical and biological similarity 
with infantile haemangiomas affecting the skin with similar rapid 
postnatal proliferation followed by spontaneous involution.
Over the past 10 years, our understanding of IHH has improved 
significantly, mainly owing to work from the Vascular Anomalies 
Centre in Boston, USA. Christison-Lagay et al.[15] published a 
seminal paper in 2007 in which they proposed a classification 
stratifying IHH into focal, multifocal and diffuse lesions (Fig. 5). 
The simultaneous development of a prospective liver haemangioma 
registry with a recommended management algorithm has helped 
to quantify the differences in presentation and prognosis, and has 
significantly advanced the understanding of the natural history of 
these lesions.[16]
Clinical features
Most IHHs present within the first 6 months of life, with an 
increasing proportion of up to 30% detected antenatally. Most studies 
suggest a female preponderance of 3:1 but this appears to apply only 
to multifocal and diffuse lesions rather than focal lesions. White 
infants are also most frequently affected.
Although histologically benign, there is a proportion of IHHs 
that produce life-threatening clinical symptoms owing to the size 
of the lesion, an abdominal compartment syndrome, and the futile 
haemodynamic shunting of blood rapidly through the liver, which 
leads to high-output cardiac failure. Less major symptoms include 
abdominal distension, hepatomegaly, or simply other cutaneous 
haemangiomas. Kasabach-Merritt syndrome describes a consumptive 
coagulopathy and platelet trapping in the interstices of the tumour 
that can be seen in ~10% of cases and is particularly ominous. 
Historically, cardiac failure has been reported in 50 - 70%, with a 
mortality rate of up to 90% in some series.[17] 
Increased antenatal detection and incidental discovery hasve 
highlighted the phenomenon of the ‘focal IHH.’ They appear to 
be clinically and biological distinct from their ‘multifocal’ and 
‘diffuse’ siblings representing the pure hepatic form of their rapidly 
involuting congenital cutaneous counterpart. The natural course 
of these lesions is one of rapid postnatal proliferation (months), 
involution (years) and finally an involuted phase during which 
endothelial cells are eventually replaced by fibro-fatty tissue. Focal 
lesions commonly regress fully postnatally and rarely require any 
form of intervention. Symptoms may rarely occur depending on 
location, size and arteriovenous shunting. Interestingly, a number 
of studies have shown cutaneous lesions are found in only 5% of 
infants with focal lesions (similar to that of the baseline population) 
while they may be present in up to 70% of infants with the 
multifocal or diffuse types.[16] Increased ultrasound screening for 
hepatic lesions where ≥5 cutaneous lesions are present has almost 
certainly contributed to the increase in the incidence of IHH seen 
in recent years.
No studies have reported antenatal detection of multifocal 
and diffuse lesions and therefore they are typically thought to 
develop postnatally, undergo proliferation for up to 1 year and 
gradually regress thereafter. In one study of 121 patients,[16] 
biological differences included immunoexpression of glucose 
transporter-1 (GLUT-1) in all resected specimens of multifocal 
and diffuse subtypes compared with no expression of GLUT-
1 in those with focal disease. There is a relationship between 
IHH and thyroid dysfunction, typically in hypothyroidism[18] but 
also hyperthyroidism;[19] however, this relationship has only been 
described in multifocal and diffuse subtypes (Table 2) . 
Investigation and management
Diagnosis is based on a combination of clinical findings and 
radiological appearance. Ultrasonography is the primary imaging 
modality and the characteristic finding is a well-defined, hypoechoic 
lesion. Cross-sectional imaging in the form of a CT or MRI scan is 
then reasonable Characteristically lesions are universally spherical 
and homogenous, and commonly hypodense. Intravenous contrast 
will show centripetal enhancement, i.e. the periphery enhances 
initially before the centre. Calcification is not infrequent. Aortic 
tapering is a common feature, as is the recruitment of other feeding 
vessels, and the inflow hepatic artery can become very hypertrophic. 
If hepatic artery ligation or embolisation is considered as a treatment 
choice, angiography (typically magnetic resonance arteriography 
nowadays) can provide an essential road map.
Focal
Multifocal
Diuse
Fig. 5. Clinical classification of infantile hepatic haemangiomas. 
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In the presence of atypical imaging findings or unexpected clinical 
behaviour, further investigation should be undertaken. The 
main differential diagnoses for focal IHHs are hepatoblastoma 
and mesenchymal hamartoma, and as such α-fetoprotein should 
be measured despite the fact that raised levels are also seen in 
IHH. Other differential diagnoses include AVMs and metastatic 
neuroblastoma although normal urinary catecholamines exclude 
the latter as a possibility. In a study by Kassarjian et al.,[20] 5% of 
cases who were initially diagnosed with IHH on characteristic 
imaging findings, were subsequently found to have a malignant 
appearance on histology. Furthermore, angiosarcoma has been 
described in resection specimens and it has been suggested that later 
age at diagnosis of multifocal IHH may increase the likelihood of 
angiosarcoma.
Due to the natural history of spontaneous regression in IHH, 
observation is the mainstay of treatment in asymptomatic patients. 
If symptomatic, supportive medical therapy in the form of diuretics, 
digoxin and assisted ventilation may be needed. Thyroid function 
should be closely monitored as hypothyroidism can have significant 
and permanent effects on neurocognitive development. Thyroxine 
supplementation may be indicated, although hypothyroidism 
is frequently reported to resolve with regression of the tumour. 
Coagulation status should be monitored and corrected appropriately.
Where necessary, medical treatment can induce regression of IHH 
beyond that expected from the natural involution of the lesion. Steroid 
therapy originated in the 1970s and for many years this was the first-
line therapy, with reported response rates of up to 45%;[20] however, it 
is not without associated risks, including growth delay, hypertension 
and cardiomyopathy. The mechanism of action is unclear but thought 
to cause vasoconstriction in the rapidly proliferating immature 
tumours. Other medical treatments have since been used as second-
line therapies including cyclophosphamide, vincristine, interferon–
alpha and radiotherapy with varying efficacy and frequently serious 
complications. The serendipitous discovery of propranolol promoting 
regression of a cutaneous haemangioma in a heart failure patient 
in 2008 has led to its extensive use as a medical treatment for 
IHH.[22] While its superiority in treating cutaneous haemangiomas 
has been proven, there is little beyond anecdotal evidence to suggest 
the same effect in IHH. Nevertheless, our experience with 29 infants 
since 2008 has been very favourable, with a decreased need for 
surgical intervention and an overall decrease  in the mortality rate 
in this, the propranolol era. Combination therapy with propranolol 
and prednisolone seems to have become the mainstay of medical 
treatment in most centres.
Regardless of the subtype of IHH, there is a cohort of patients 
who will not respond to medical therapy and for them surgery is 
advocated. The approach chosen is based on tumour size, localisation, 
anatomy of feeding and draining vessels, and cardiorespiratory 
condition. Where possible, focal lesions are most commonly treated 
with surgical resection – this offers complete resolution.
Hepatic artery ligation[19] or more recently embolisation if 
expertise is available, has been shown to be a safe and effective 
treatment for predominantly multifocal and diffuse bilobar disease 
as these are artery-dependent. Ligation is well tolerated if perfusion 
and oxygenation can be maintained and dramatically reduces 
arteriovenous shunting and initiates tumour regression. In the event 
of extensive involvement and no response to alternative therapy, 
liver transplantation may still be indicated although the rate of 
transplantation was <2% in our experience.
Conclusion 
Congenital hepatic vascular malformations are a rare and diverse 
group of anomalies. CPSs have a wide range of possible clinical 
manifestations and can be a cause of major morbidity, while IHH 
can be life-threatening. Recent advances in medical and surgical 
therapy now means that most cases can be treated effectively with 
preservation of the native liver. 
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